drugset / Trial / NCT01558323

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323

Phase 1 Completed 58 enrolled Novartis Pharmaceuticals
Parallel-groupOpen-labelOther

Summary

This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects

Timeline

Start
2012-05
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pradigastat Small molecule 40 mg Oral